Semaglutide mimics the action of endogenous GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways
With GLP-1 identified, researchers immediately recognized its therapeutic potential: if one could harness GLP-1s potent glucose-lowering and appetite-suppressing effects , it might become a treatment for diabetes or even obesity
The phase 2b SYMMETRY trial, a multicenter, randomized, double-blind, placebo-controlled study, included 181 patients with compensated cirrhosis (Child-Pugh A) due to MASH (78% with histological diagnosis and 22% with cryptogenic cirrhosis attributed to MASH) assigned to receive efruxifermin at doses of 28 or 50 mg, or placebo (1:1:1), for 96 weeks
Call it the Underworld of Healthcare